Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.
Zwierenga F, van Veggel BAMH, van den Berg A, Groen HJM, Zhang L, Groves MR, Kok K, Smit EF, Hiltermann TJN, de Langen AJ, van der Wekken AJ. Zwierenga F, et al. Among authors: kok k. Cancer Treat Rev. 2023 Nov;120:102628. doi: 10.1016/j.ctrv.2023.102628. Epub 2023 Sep 19. Cancer Treat Rev. 2023. PMID: 37797348 Free article. Review.
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P, Koopman B, Kok K, Ter Elst A, Schuuring E, van Kempen LC, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, van der Wekken AJ. Meng P, et al. Among authors: kok k. Lung Cancer. 2020 Aug;146:358-361. doi: 10.1016/j.lungcan.2020.05.036. Epub 2020 Jun 4. Lung Cancer. 2020. PMID: 32534795 Free article.
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC.
Wei J, Meng P, Terpstra MM, van Rijk A, Tamminga M, Scherpen F, Ter Elst A, Alimohamed MZ, Johansson LF, Stigt J, Gijtenbeek RPG, van Putten J, Hiltermann TJN, Groen HJM, Kok K, van der Wekken AJ, van den Berg A. Wei J, et al. Among authors: kok k. Target Oncol. 2021 Mar;16(2):215-226. doi: 10.1007/s11523-021-00798-2. Epub 2021 Feb 19. Target Oncol. 2021. PMID: 33606136 Free PMC article.
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM. van der Wekken AJ, et al. Among authors: kok k. PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017. PLoS One. 2017. PMID: 28854272 Free PMC article.
420 results